CN108277386A - A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof - Google Patents
A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof Download PDFInfo
- Publication number
- CN108277386A CN108277386A CN201810244009.5A CN201810244009A CN108277386A CN 108277386 A CN108277386 A CN 108277386A CN 201810244009 A CN201810244009 A CN 201810244009A CN 108277386 A CN108277386 A CN 108277386A
- Authority
- CN
- China
- Prior art keywords
- kirsite
- zinc alloy
- zinc
- systems
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910006309 Li—Mg Inorganic materials 0.000 title claims abstract description 77
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 229910001297 Zn alloy Inorganic materials 0.000 claims abstract description 88
- 239000011701 zinc Substances 0.000 claims abstract description 41
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 38
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 22
- 239000007943 implant Substances 0.000 claims abstract description 19
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 16
- 238000001125 extrusion Methods 0.000 claims description 23
- 239000000463 material Substances 0.000 claims description 23
- 210000000988 bone and bone Anatomy 0.000 claims description 19
- 238000005096 rolling process Methods 0.000 claims description 17
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 239000011573 trace mineral Substances 0.000 claims description 11
- 235000013619 trace mineral Nutrition 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 238000005242 forging Methods 0.000 claims description 7
- 238000005098 hot rolling Methods 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010791 quenching Methods 0.000 claims description 5
- 230000000171 quenching effect Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 239000005548 dental material Substances 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 239000003356 suture material Substances 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 229910052709 silver Inorganic materials 0.000 claims description 3
- 239000004332 silver Substances 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000007731 hot pressing Methods 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 229910052712 strontium Inorganic materials 0.000 claims description 2
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- 239000011135 tin Substances 0.000 claims description 2
- 206010034122 Patella fracture Diseases 0.000 claims 1
- 210000003445 biliary tract Anatomy 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 238000007711 solidification Methods 0.000 claims 1
- 230000008023 solidification Effects 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
- 210000003708 urethra Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000007774 longterm Effects 0.000 abstract description 5
- 230000008093 supporting effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000011777 magnesium Substances 0.000 description 23
- 239000000956 alloy Substances 0.000 description 20
- 229910045601 alloy Inorganic materials 0.000 description 18
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 210000002889 endothelial cell Anatomy 0.000 description 10
- 239000012620 biological material Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 230000007797 corrosion Effects 0.000 description 7
- 238000005260 corrosion Methods 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000963 osteoblast Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002386 leaching Methods 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 238000007712 rapid solidification Methods 0.000 description 4
- 239000012890 simulated body fluid Substances 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 238000004506 ultrasonic cleaning Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000000840 electrochemical analysis Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 239000007769 metal material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 238000003723 Smelting Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006056 electrooxidation reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 description 1
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 1
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910008088 Li-Mn Inorganic materials 0.000 description 1
- 229910006327 Li—Mn Inorganic materials 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000010405 anode material Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 230000028956 calcium-mediated signaling Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229910000765 intermetallic Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- KUJOABUXCGVGIY-UHFFFAOYSA-N lithium zinc Chemical compound [Li].[Zn] KUJOABUXCGVGIY-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 229910001000 nickel titanium Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C18/00—Alloys based on zinc
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/84—Preparations for artificial teeth, for filling teeth or for capping teeth comprising metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/047—Other specific metals or alloys not covered by A61L27/042 - A61L27/045 or A61L27/06
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22C—ALLOYS
- C22C1/00—Making non-ferrous alloys
- C22C1/02—Making non-ferrous alloys by melting
-
- C—CHEMISTRY; METALLURGY
- C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
- C22F—CHANGING THE PHYSICAL STRUCTURE OF NON-FERROUS METALS AND NON-FERROUS ALLOYS
- C22F1/00—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
- C22F1/16—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of other metals or alloys based thereon
- C22F1/165—Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of other metals or alloys based thereon of zinc or cadmium or alloys based thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Metallurgy (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Thermal Sciences (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Prostheses (AREA)
Abstract
本发明公开了一种Zn‑Li‑Mg系锌合金及其制备方法与应用。本发明所述锌合金包括Zn、Li和Mg;以重量百分比计,所述锌合金中Li的质量百分数为0~1%,但不包括0;所述锌合金中Mg的质量百分数为0~1%,但不包括0;余量为锌。本发明制备的锌合金力学性能优异,能够在体内提供长期有效的支撑力,具有优异的细胞相容性和血液相容性,可用于生物医用植入物的制备。The invention discloses a Zn-Li-Mg series zinc alloy as well as a preparation method and application thereof. The zinc alloy of the present invention includes Zn, Li and Mg; in terms of weight percentage, the mass percentage of Li in the zinc alloy is 0 to 1%, but 0 is not included; the mass percentage of Mg in the zinc alloy is 0 to 1%. 1%, but not including 0; the balance being zinc. The zinc alloy prepared by the invention has excellent mechanical properties, can provide long-term effective supporting force in vivo, has excellent cell compatibility and blood compatibility, and can be used for the preparation of biomedical implants.
Description
技术领域technical field
本发明涉及一种Zn-Li-Mg系锌合金及其制备方法与应用,属于医用金属材料制备技术领域。The invention relates to a Zn-Li-Mg series zinc alloy and its preparation method and application, belonging to the technical field of medical metal material preparation.
背景技术Background technique
使用生物材料制作的医疗器械,在植入生物有机体内后,会与有机体发生相互作用。这些作用可用于辅助诊断、治疗或者帮助有机体病损组织器官修复、替换。很显然,根据植入医疗器械的目的不同,其所适宜的植入时间长度也不尽相同:有些器械适合在体内长期存在,从而达到长期服役促进疗效的目的;而有些器械只需暂时或短时起作用,因此需要在生物组织或器官的修复或再生过程中,这些器械逐步被降解、吸收。Medical devices made of biomaterials will interact with organisms after being implanted in them. These functions can be used for auxiliary diagnosis, treatment or to help the repair and replacement of damaged tissues and organs of the organism. Obviously, depending on the purpose of implanting medical devices, the appropriate length of implantation time is also different: some devices are suitable for long-term existence in the body, so as to achieve the purpose of long-term service to promote curative effect; while some devices only need to be temporarily or short-term. Therefore, these devices need to be gradually degraded and absorbed during the repair or regeneration of biological tissues or organs.
根据不同使用目的,植入有机体的生物材料可大体分为永久性生物材料和可降解生物材料两大类。其中永久性生物材料包括永久性金属生物材料、永久性陶瓷材料和永久性高分子材料。而所谓永久性金属生物材料,主要包括不锈钢、钴基合金、钛及钛合金、镍钛形状记忆合金、锆基合金、钽和金、银、铂等贵金属。目前永久性金属生物材料是生物医用材料中用量最大的一类。这类材料具有良好的强度和韧性、杰出的耐腐蚀和抗疲劳性能、以及优异的加工性能,现已广泛应用于心血管植介入治疗和人体硬组织修复(如骨骼、牙齿、关节等修复及替换)等领域。According to different purposes, biomaterials implanted into organisms can be roughly divided into two categories: permanent biomaterials and degradable biomaterials. The permanent biomaterials include permanent metal biomaterials, permanent ceramic materials and permanent polymer materials. The so-called permanent metal biomaterials mainly include stainless steel, cobalt-based alloys, titanium and titanium alloys, nickel-titanium shape memory alloys, zirconium-based alloys, tantalum and precious metals such as gold, silver, and platinum. At present, permanent metal biomaterials are the most used type of biomedical materials. This kind of material has good strength and toughness, outstanding corrosion resistance and fatigue resistance, and excellent processing performance, and has been widely used in cardiovascular implant intervention therapy and human hard tissue repair (such as bone, tooth, joint and other repair and Replacement) and other fields.
可降解金属是本世纪初开始迅速发展的以镁基合金和铁基合金为代表的一类新型医用金属材料,这类材料突破了以往只是将金属植入物作为生物惰性材料使用的传统想法,而是另辟蹊径,巧妙地利用植入金属在人体环境(含氯离子)中容易发生腐蚀(降解)的特性,期待能以可控方式实现金属植入物在体内的修复功能,并最终在人体组织完成重建/功能修复之后完全降解为对人体无害的金属离子和其他产物。但铁基合金、镁基合金两种材料各有其不足之处。最初被研究的可降解金属是铁基合金,其缺点是在人体内降解速度过慢,且降解产物对人体有一定的毒副作用,因此后来镁基合金(如AZ31、WE43、Mg-Ca等)逐渐成为研究热点。尽管镁基合金作为生物材料有着诱人的应用前景,但研究发现,镁基合金腐蚀速度过快,在组织器官没有充分愈合之前,植入物便很快会丧失其机械完整性。为了满足实际临床需求,有必要开发新型的生物可降解金属。Degradable metals are a new class of medical metal materials represented by magnesium-based alloys and iron-based alloys that have developed rapidly since the beginning of this century. These materials have broken through the traditional idea of using metal implants as biologically inert materials. Instead, it is a new way to cleverly use the characteristics of implanted metals that are prone to corrosion (degradation) in the human body environment (containing chloride ions), expecting to realize the repair function of metal implants in the body in a controllable manner, and finally in human tissue. After completion of reconstruction/function repair, it is completely degraded into metal ions and other products that are harmless to the human body. However, the two materials of iron-based alloy and magnesium-based alloy have their own shortcomings. The degradable metals that were initially studied were iron-based alloys. The disadvantages were that the degradation rate in the human body was too slow, and the degradation products had certain toxic and side effects on the human body. Therefore, magnesium-based alloys (such as AZ31, WE43, Mg-Ca, etc.) gradually become a research hotspot. Although magnesium-based alloys have attractive application prospects as biomaterials, studies have found that magnesium-based alloys corrode too quickly, and implants will quickly lose their mechanical integrity before tissues and organs are fully healed. In order to meet the actual clinical needs, it is necessary to develop novel biodegradable metals.
在工业领域,锌金属及其合金是常用的金属材料。在工业上,锌金属及其合金因为具有化学性质活泼、易于腐蚀的特点,所以常常被用作电化学腐蚀保护中被牺牲的阳极材料。但与镁相比,锌金属及其合金的腐蚀电位更高,腐蚀速率更慢,因此更加符合实际临床需要,有望成为新型生物医用可降解植入材料及器件。In the industrial field, zinc metal and its alloys are commonly used metal materials. In industry, zinc metal and its alloys are often used as sacrificial anode materials in electrochemical corrosion protection because of their active chemical properties and easy corrosion. However, compared with magnesium, zinc metal and its alloys have higher corrosion potential and slower corrosion rate, so they are more in line with actual clinical needs and are expected to become new biomedical degradable implant materials and devices.
在生命科学领域,锌也同样具有重要地位。锌是人体中丰富程度仅次于铁的第二号元素。人体含锌总量约占体重0.003%,其中90%存在于肌肉和骨骼,10%存在于血液中。根据不同年龄,锌的人体推荐每日摄入量(RDA)在2-13mg之间。人体主要通过小肠吸收锌,主要储存于肝、肾之中,在细胞内与金属蛋白进行结合。In the field of life sciences, zinc also plays an important role. Zinc is the second most abundant element in the human body after iron. The total amount of zinc in the human body accounts for about 0.003% of the body weight, 90% of which exists in the muscles and bones, and 10% exists in the blood. According to different ages, the recommended daily intake (RDA) of zinc is between 2-13mg. The human body mainly absorbs zinc through the small intestine, mainly stores it in the liver and kidney, and combines it with metalloproteins in the cells.
锌是300多种酶的组成成分,能够维持免疫功能和促进生长发育。锌可以调节生物基因表现,例如促进胰岛素分泌,通过促进吞噬功能和产生免疫球蛋白来提高生物体免疫力。锌可以保护心肌细胞免受急性氧化应激损伤,在心肌损伤时预防炎症反应,促进伤口愈合,并在心肌恢复的过程中促进心肌干细胞的存活。动脉粥样硬化一般伴随着内皮细胞损伤。有研究表明锌可以保护内皮细胞并保持其完整性,锌通过调控转录因子NF-kB与DNA的结合来调控细胞的凋亡和炎症反应。在内皮细胞内,锌通过抑制NF-kB的活性,减少内皮细胞粘附蛋白的表达,从而降低动脉粥样硬化的风险。体外细胞实验显示,锌离子在低浓度时能够促进内皮细胞和平滑肌细胞的增殖、粘附和迁移,而高浓度时则作用相反。受锌离子影响的相关基因与细胞粘附、损伤、生长、成血管、炎症、凝血有关。对于内皮细胞和平滑肌细胞,这个浓度分别约为100μM和80μM。在骨环境中,成骨细胞内的锌通过激活tRNA合成酶和刺激基因表达来促进蛋白质的合成,同时也增加细胞内DNA数量,从而促进成骨细胞新骨生成和矿化。同时,锌通过调控钙离子信号通路,促进破骨细胞的的凋亡。锌通过促成骨和抑制骨吸收最终使骨质量增加,与其他微量元素相比,锌在骨的新陈代谢中的毒性最小。缺锌会引起表皮,肠道,中枢神经,免疫系统,骨骼和生殖系统产生一系列的相关问题。Zinc is a component of more than 300 enzymes that support immune function and promote growth and development. Zinc can regulate the expression of biological genes, such as promoting insulin secretion, and improving the immunity of organisms by promoting phagocytosis and producing immunoglobulins. Zinc can protect cardiomyocytes from acute oxidative stress injury, prevent inflammatory response during myocardial injury, promote wound healing, and promote the survival of myocardial stem cells during myocardial recovery. Atherosclerosis is generally accompanied by endothelial cell damage. Studies have shown that zinc can protect endothelial cells and maintain their integrity. Zinc regulates cell apoptosis and inflammation by regulating the combination of transcription factor NF-kB and DNA. In endothelial cells, zinc reduces the risk of atherosclerosis by inhibiting the activity of NF-kB and reducing the expression of endothelial cell adhesion proteins. In vitro cell experiments have shown that zinc ions can promote the proliferation, adhesion and migration of endothelial cells and smooth muscle cells at low concentrations, but have the opposite effect at high concentrations. Related genes affected by zinc ions are related to cell adhesion, injury, growth, angiogenesis, inflammation, and coagulation. For endothelial cells and smooth muscle cells, this concentration is approximately 100 μM and 80 μM, respectively. In the bone environment, zinc in osteoblasts promotes protein synthesis by activating tRNA synthetase and stimulating gene expression, and also increases the amount of DNA in cells, thereby promoting new bone formation and mineralization of osteoblasts. At the same time, zinc promotes the apoptosis of osteoclasts by regulating the calcium ion signaling pathway. Zinc ultimately increases bone mass by promoting bone formation and inhibiting bone resorption. Compared with other trace elements, zinc has the least toxicity in bone metabolism. Zinc deficiency can cause a series of related problems in the epidermis, intestinal tract, central nervous system, immune system, bone and reproductive system.
发明内容Contents of the invention
本发明的目的是提供一种Zn-Li-Mg系锌合金及其制备方法与应用,本发明制备的锌合金力学性能优异,能够在体内提供长期有效的支撑力,具有优异的细胞相容性和血液相容性,可用于生物医用植入物的制备。The purpose of the present invention is to provide a Zn-Li-Mg series zinc alloy and its preparation method and application. The zinc alloy prepared by the present invention has excellent mechanical properties, can provide long-term effective supporting force in the body, and has excellent cell compatibility Compatible with blood, it can be used in the preparation of biomedical implants.
本发明提供的一种Zn-Li-Mg系锌合金,它包括Zn、Li和Mg;A kind of Zn-Li-Mg system zinc alloy provided by the invention, it comprises Zn, Li and Mg;
以重量百分比计,所述锌合金中Li的质量百分数为0~1%,但不包括0;所述锌合金中Mg的质量百分数为0~1%,但不包括0;余量为锌。In terms of weight percentage, the mass percentage of Li in the zinc alloy is 0-1%, but not including 0; the mass percentage of Mg in the zinc alloy is 0-1%, but not including 0; the balance is zinc.
上述的锌合金中,所述锌合金还包括微量元素;In the above-mentioned zinc alloy, the zinc alloy also includes trace elements;
所述锌合金中,所述微量元素的质量百分含量为0~3%,但不包括0;In the zinc alloy, the mass percentage of the trace elements is 0-3%, but 0% is not included;
所述微量元素为锰、锶、钙、硅、磷、银、铜、锡、铁和稀土元素中的至少一种。本发明提供的Zn-Li-Mg系锌合金具体为下述1)-9)中任一种,为重量百分比:The trace element is at least one of manganese, strontium, calcium, silicon, phosphorus, silver, copper, tin, iron and rare earth elements. The Zn-Li-Mg series zinc alloy provided by the present invention is specifically any one of the following 1)-9), which is the percentage by weight:
1)由99.8%的Zn,0.1%的Li和0.1%Mg组成;1) Composed of 99.8% Zn, 0.1% Li and 0.1% Mg;
2)由99.5%的Zn,0.1%的Li和0.4%Mg组成;2) Composed of 99.5% Zn, 0.1% Li and 0.4% Mg;
3)由99.1%的Zn,0.1%的Li和0.8%Mg组成;3) Composed of 99.1% Zn, 0.1% Li and 0.8% Mg;
4)由99.5%的Zn,0.4%的Li和0.1%Mg组成;4) Composed of 99.5% Zn, 0.4% Li and 0.1% Mg;
5)由99.2%的Zn,0.4%的Li和0.4%Mg组成;5) Composed of 99.2% Zn, 0.4% Li and 0.4% Mg;
6)由98.8%的Zn,0.4%的Li和0.8%Mg组成;6) Composed of 98.8% Zn, 0.4% Li and 0.8% Mg;
7)由99.1%的Zn,0.8%的Li和0.1%Mg组成;7) Composed of 99.1% Zn, 0.8% Li and 0.1% Mg;
8)由98.8%的Zn,0.8%的Li和0.4%Mg组成;8) Composed of 98.8% Zn, 0.8% Li and 0.4% Mg;
9)由98.4%的Zn,0.8%的Li和0.8%Mg组成。9) Composed of 98.4% Zn, 0.8% Li and 0.8% Mg.
本发明还提供了上述Zn-Li-Mg系锌合金的制备方法,包括如下步骤:(1)按照所述锌合金中质量百分比称取含所述Zn、所述Li和所述Mg原料混合,得到混合物;The present invention also provides a method for preparing the above-mentioned Zn-Li-Mg zinc alloy, comprising the following steps: (1) weighing and mixing raw materials containing the Zn, the Li and the Mg according to the mass percentage of the zinc alloy, get the mixture;
(2)在CO2和SF6气氛保护下,将所述混合物进行熔炼,然后经浇注、冷却,即得到所述Zn-Li-Mg系锌合金。(2) Under the protection of CO 2 and SF 6 atmosphere, the mixture is melted, then poured and cooled to obtain the Zn-Li-Mg zinc alloy.
上述的制备方法中,步骤(1)中还包括加入所述微量元素混合的步骤;In the above-mentioned preparation method, step (1) also includes the step of adding said trace elements and mixing;
所述方法还包括将所述混合物进行熔炼后进行静置的步骤;所述静置的目的是让杂质沉降、提高制备所述锌合金材料的纯度;The method also includes the step of smelting the mixture and then standing still; the purpose of standing still is to allow impurities to settle and improve the purity of the zinc alloy material prepared;
所述熔炼的温度可为420~600℃,具体可为600℃。The melting temperature may be 420-600°C, specifically 600°C.
上述的制备方法中,所述方法还包括对所述Zn-Li-Mg系锌合金进行机械加工的步骤;In the above preparation method, the method further includes the step of mechanically processing the Zn-Li-Mg zinc alloy;
所述机械加工为挤压、轧制、锻造和快速凝固中至少一种。The machining is at least one of extrusion, rolling, forging and rapid solidification.
上述的制备方法中,所述方法中在所述机械加工之前对所述Zn-Li-Mg系锌合金进行均匀化处理的步骤;所述处理的温度可为300~400摄氏度,时间可为12~48小时;所述均匀化处理后进行水淬、油淬或空冷(即在空气中冷却);In the above-mentioned preparation method, in the method, the step of homogenizing the Zn-Li-Mg series zinc alloy before the mechanical processing; the temperature of the treatment can be 300-400 degrees Celsius, and the time can be 12 ~48 hours; water quenching, oil quenching or air cooling (that is, cooling in air) after the homogenization treatment;
所述挤压的温度可为150~280℃,挤压比可为10~70,挤压速度可为0.1~10mm/s;所述挤压的温度具体可为260℃或220℃,挤压比具体可为36或16,挤压速度具体可为1mm/s制备出直径具体可为10mm;所述挤压之前包括保温的步骤,具体可为保温2h,保温温度260℃或220℃;The extrusion temperature can be 150-280°C, the extrusion ratio can be 10-70, and the extrusion speed can be 0.1-10mm/s; the extrusion temperature can be 260°C or 220°C, and the extrusion The specific ratio can be 36 or 16, the extrusion speed can be specifically 1mm/s, and the diameter can be specifically 10mm; the step of heat preservation is included before the extrusion, specifically, it can be heat preservation for 2 hours, and the heat preservation temperature is 260°C or 220°C;
所述轧制包括依次进行热轧和精轧,所述热轧在200~300℃下进行,所述精轧在150~250℃下进行,每道次轧下量1~20%,所述Zn-Li-Mg系锌合金被轧制1~3mm;所述轧制包括保温的步骤,具体可为温度270℃下保温15分钟;The rolling includes hot rolling and finish rolling in sequence, the hot rolling is carried out at 200-300°C, the finish rolling is carried out at 150-250°C, and the rolling reduction per pass is 1-20%. The Zn-Li-Mg series zinc alloy is rolled for 1-3 mm; the rolling includes the step of heat preservation, specifically, heat preservation at a temperature of 270° C. for 15 minutes;
所述锻造包括将所述Zn-Li-Mg系锌合金在150~200℃的条件下进行保温,然后在200~300℃的条件下进行锻造的步骤,所述保温的时间为3~50小时,所述锻造的速率不小于350mm/s;The forging includes the step of keeping the Zn-Li-Mg zinc alloy at 150-200°C and then forging at 200-300°C, and the holding time is 3-50 hours , the forging speed is not less than 350mm/s;
所述快速凝固包括如下步骤:在惰性气氛保护下,采用高真空快淬系统将所述Zn-Li-Mg系锌合金制成快速凝固薄带,然后将所述薄带破碎成粉末状,最后在200~350℃的条件下,真空热压1~24h。The rapid solidification includes the following steps: under the protection of an inert atmosphere, the Zn-Li-Mg series zinc alloy is made into a rapid solidification thin strip by using a high vacuum rapid quenching system, and then the thin strip is broken into powder, and finally Under the condition of 200-350°C, vacuum hot pressing for 1-24h.
本发明中,所述快速凝固中采用的惰性气氛具体可为氩气;In the present invention, the inert atmosphere used in the rapid solidification may specifically be argon;
所述高真空快淬系统的设置如下:加料量2~8g、感应加热功率为3~7kW、喷嘴与辊间距为0.80mm、喷射压力为0.05~0.2MPa、辊轮转速为500~3000r/min及喷嘴狭缝尺寸为1film×8mm×6mm。The settings of the high vacuum rapid quenching system are as follows: feeding amount 2-8g, induction heating power 3-7kW, distance between nozzle and roller 0.80mm, injection pressure 0.05-0.2MPa, roller speed 500-3000r/min And the nozzle slit size is 1film×8mm×6mm.
上述的制备方法中,所述方法还包括将所述锌合金加工成毛细管材的步骤。In the above preparation method, the method further includes the step of processing the zinc alloy into a capillary tube.
本发明中,所述锌合金加工成毛细管材的方法,具体包括吐下步骤:(1)将所述锌合金铸锭加热至150~280℃,保温0.5~1小时,预热棒材挤压磨具200~350℃,以16~36挤压比对铸锭进行挤压,挤压速度0.1~10mm/s,得到直径10mm的棒材;(2)将挤压的得到的棒材截取10~50mm加工成管坯,作为挤压毛细管用;(3)将管坯放入分流挤压模具中进行挤压,挤压温度150~280℃,挤压比16~64,挤压模冲头速度20~30mm/s,得到外径尺寸2~5mm,壁厚0.1~0.5mm,长度300~1000mm的毛细管;(4)将上述毛细管于100~300℃范围内进行0.5~24小时去应力退火处理,得到Zn合金毛细管材。In the present invention, the method for processing the zinc alloy into a capillary tube specifically includes the following steps: (1) heating the zinc alloy ingot to 150-280°C, keeping it warm for 0.5-1 hour, and extruding the preheated rod The grinding tool is 200-350°C, and the ingot is extruded with an extrusion ratio of 16-36, and the extrusion speed is 0.1-10mm/s to obtain a rod with a diameter of 10mm; (2) Cut the extruded rod into 10 ~50mm is processed into a tube billet, which is used as an extrusion capillary; (3) Put the tube billet into a split extrusion die for extrusion, the extrusion temperature is 150-280 ° C, the extrusion ratio is 16-64, the extrusion die punch The speed is 20-30mm/s to obtain a capillary with an outer diameter of 2-5mm, a wall thickness of 0.1-0.5mm, and a length of 300-1000mm; (4) The above-mentioned capillary is subjected to stress relief annealing at 100-300°C for 0.5-24 hours treatment to obtain a Zn alloy capillary tube.
本发明还提供了上述Zn-Li-Mg系锌合金在制备可体液降解医用植入体中的应用。The present invention also provides the application of the above-mentioned Zn-Li-Mg zinc alloy in the preparation of biodegradable medical implants.
上述的应用中,所述应用包括下述1)-4)中任一种:In the above-mentioned application, the application includes any one of the following 1)-4):
1)所述Zn-Li-Mg系锌合金作为可降解支架的应用,所述支架包括血管支架、食道支架、肠道支架、气管支架、胆道支架、尿道支架和前列腺支架中的至少一种;1) The Zn-Li-Mg series zinc alloy is used as a degradable stent, and the stent includes at least one of a vascular stent, an esophageal stent, an intestinal stent, a tracheal stent, a biliary stent, a urethral stent, and a prostate stent;
2)所述Zn-Li-Mg系锌合金作为可降解骨科用植入物的应用,所述骨科植入物包括骨板、骨钉、骨针、骨棒、脊柱内固定器材、结扎丝、聚髌器、骨蜡、骨修复材料、骨组织修复支架、髓内针和接骨套中的至少一种;2) The application of the Zn-Li-Mg zinc alloy as a degradable orthopedic implant, the orthopedic implant includes bone plates, bone nails, bone needles, bone rods, spinal internal fixation equipment, ligature wires, At least one of patella concentrator, bone wax, bone repair material, bone tissue repair bracket, intramedullary nail and bone sleeve;
3)所述Zn-Li-Mg系锌合金作为可降解缝合材料的应用,所述缝合材料包括可吸收缝合线、皮肤缝合钉和医用拉链中的至少一种。3) Application of the Zn-Li-Mg series zinc alloy as a degradable suture material, and the suture material includes at least one of absorbable sutures, skin staples and medical zippers.
4)所述Zn-Li-Mg系锌合金作为齿科材料的应用,所述齿科材料包括齿科植入材料、根管锉和牙齿充填材料中的至少一种。4) Application of the Zn-Li-Mg zinc alloy as a dental material, the dental material includes at least one of dental implant materials, root canal files and tooth filling materials.
本发明中,所述Zn-Li-Mg系锌合金具备其下述a)-d)性能可用于制备可体液降解医用植入体:In the present invention, the Zn-Li-Mg series zinc alloy has the following a)-d) properties and can be used to prepare body fluid degradable medical implants:
a)所述Zn-Li-Mg系锌合金优异的综合力学性能,包括强度、硬度和塑性;a) the excellent comprehensive mechanical properties of the Zn-Li-Mg series zinc alloy, including strength, hardness and plasticity;
b)所述Zn-Li-Mg系锌合金的血液相容性;b) blood compatibility of the Zn-Li-Mg zinc alloy;
c)所述Zn-Li-Mg系锌合金的细胞相容性;c) the cytocompatibility of the Zn-Li-Mg series zinc alloy;
d)所述Zn-Li-Mg系锌合金的可降解性。d) Degradability of the Zn-Li-Mg series zinc alloy.
本发明进一步提供了一种可体液降解医用植入体,该植入体采用所述Zn-Li-Mg系锌合金制备得到。The present invention further provides a body fluid degradable medical implant, which is prepared by using the Zn-Li-Mg zinc alloy.
本发明具有以下优点:The present invention has the following advantages:
(1)本发明制备的Zn-Li-Mg系合金的机械性能优异,同时具备优良力学性能,能够满足体内不同部位的要求。同时又可以在体内被吸收、自然降解,具有“可调控的体内腐蚀降解特性”和“提供有效的力学支撑”的特点。(1) The Zn-Li-Mg alloy prepared by the present invention has excellent mechanical properties, and at the same time has excellent mechanical properties, which can meet the requirements of different parts in the body. At the same time, it can be absorbed and degraded naturally in the body, and has the characteristics of "controllable corrosion degradation characteristics in vivo" and "providing effective mechanical support".
(2)本发明Zn-Li-Mg系合金用于可降解医用植入体时,在植入体内后可以为受伤部位提供长期有效的医学支撑保护作用(如固定保护骨组织或者支撑狭窄的血管),又能在组织修复的同时,逐渐被体内环境吸收、降解。材料数量和体积逐渐减少,材料的降解产物和释放出的离子能够被机体吸收、代谢,帮助机体恢复并逐渐的排出体外,在机体完全恢复后,材料完全被吸收降解,无需二次取出。(2) When the Zn-Li-Mg alloy of the present invention is used for degradable medical implants, it can provide long-term effective medical support and protection for injured parts after being implanted in the body (such as fixing and protecting bone tissue or supporting narrow blood vessels) ), and can be gradually absorbed and degraded by the internal environment while tissue repairing. The quantity and volume of the material gradually decrease, and the degradation products and released ions of the material can be absorbed and metabolized by the body to help the body recover and be gradually excreted from the body. After the body fully recovers, the material is completely absorbed and degraded, and there is no need to take it out again.
(3)本发明提供的锌合金由Zn、Li、Mg组成,均为人体内所需的微量元素,在体内降解可以被人体自然代谢,具有生物安全性。(3) The zinc alloy provided by the present invention is composed of Zn, Li, and Mg, all of which are trace elements required in the human body, can be naturally metabolized by the human body when degraded in the body, and have biological safety.
(4)本发明提供的锌合金中,除纯锌外,均为微量元素,即微合金化,能够在获得优异性能的同时,使材料的成分简化,有利于为后续材料的安全性和有效性研究提供方便。(4) In the zinc alloy provided by the present invention, except for pure zinc, all are trace elements, that is, microalloying, which can simplify the composition of the material while obtaining excellent performance, which is conducive to the safety and effectiveness of subsequent materials. facilitated research.
(5)本发明提供的锌合金中Li元素起到显著强化基体的效果,Mg元素进一步提高力学强度,并可以起到促进成骨的效果,通过调整不同元素的种类和成分,可以获得力学性能,降解性能和功能不同的合金材料,分别应用于体内不同环境下植入器械。(5) The Li element in the zinc alloy provided by the present invention can significantly strengthen the matrix, the Mg element can further improve the mechanical strength, and can promote the effect of osteogenesis, and the mechanical properties can be obtained by adjusting the types and components of different elements , alloy materials with different degradation properties and functions are applied to implant devices in different environments in the body.
(6)本发明提供的锌合金可获得强度为391~681MPa,延伸率为1.39%~8.92%的棒材或板材,具有优异的强度,其中成分为Zn0.8Li0.1Mg的锌合金前强度为681MPa,是目前报道的可降解锌合金中延伸率最高的锌合金,降解速率1.74mm/year附近。材料对内皮细胞,平滑肌细胞和成骨细胞均无毒性,能够促进内皮和成骨细胞增殖,血液相容性优异,且加入Mg可以产生促成骨的作用,锌合金本身还有抗菌效果,可以制备一些有特殊用途的医疗器械。(6) the zinc alloy provided by the present invention can obtain strength and be 391~681MPa, elongation rate is 1.39%~8.92% rod or plate, has excellent strength, and wherein composition is the zinc alloy front strength of Zn0.8Li0.1Mg is 681MPa, which is the zinc alloy with the highest elongation among the reported degradable zinc alloys, and the degradation rate is around 1.74mm/year. The material is non-toxic to endothelial cells, smooth muscle cells and osteoblasts, can promote endothelial and osteoblast proliferation, has excellent blood compatibility, and the addition of Mg can produce the effect of promoting osteogenesis. Zinc alloy itself has antibacterial effect and can be prepared Some medical devices with special purposes.
附图说明Description of drawings
图1为本发明实施例1制备的Zn-Li-Mg系锌合金铸锭的照片。Fig. 1 is a photograph of a Zn-Li-Mg zinc alloy ingot prepared in Example 1 of the present invention.
图2为本发明实施例2制备的Zn-Li-Mg系锌合金棒材的照片。Fig. 2 is a photo of the Zn-Li-Mg system zinc alloy rod prepared in Example 2 of the present invention.
图3为本发明实施例3制备的Zn-Li-Mg系锌合金板材的照片。Fig. 3 is a photo of the Zn-Li-Mg zinc alloy plate prepared in Example 3 of the present invention.
图4为本发明实施例1制备的Zn-Li-Mg系锌合金的应力应变曲线。Fig. 4 is a stress-strain curve of the Zn-Li-Mg system zinc alloy prepared in Example 1 of the present invention.
图5为本发明Zn-Li-Mg系锌合金在模拟体液中的电化学腐蚀曲线。Fig. 5 is the electrochemical corrosion curve of the Zn-Li-Mg system zinc alloy of the present invention in simulated body fluid.
图6为平滑肌细胞在本发明Zn-Li-Mg系锌合金100%浸提液中的相对存活率。Fig. 6 is the relative survival rate of smooth muscle cells in 100% leaching solution of Zn-Li-Mg zinc alloy of the present invention.
图7为HUVEC人脐静脉内皮细胞在本发明Zn-Li-Mg系锌合金100%浸提液中的相对存活率。Fig. 7 is the relative survival rate of HUVEC human umbilical vein endothelial cells in the 100% extraction solution of Zn-Li-Mg zinc alloy of the present invention.
图8为MC3T3-E1小鼠成骨细胞在本发明Zn-Li-Mg系锌合金100%浸提液中的相对存活率。Fig. 8 shows the relative survival rate of MC3T3-E1 mouse osteoblasts in the 100% leaching solution of Zn-Li-Mg zinc alloy of the present invention.
图9为人血小板粘附在本发明Zn-Li-Mg系锌合金表面的形态。Fig. 9 shows the morphology of human platelets adhered to the surface of the Zn-Li-Mg zinc alloy of the present invention.
具体实施方式Detailed ways
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。The experimental methods used in the following examples are conventional methods unless otherwise specified.
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。The materials and reagents used in the following examples can be obtained from commercial sources unless otherwise specified.
实施例1、制备铸态Zn-Li-Mg系锌合金Embodiment 1, preparation as-cast Zn-Li-Mg system zinc alloy
以纯锌(99.99wt.%)、纯镁(99.9wt.%)、锌锂金属间化合物作为原料,按照下表的质量比:Using pure zinc (99.99wt.%), pure magnesium (99.9wt.%), and zinc-lithium intermetallic compounds as raw materials, according to the mass ratio in the following table:
混合,在CO2+SF6气氛保护下,600℃熔炼,搅拌均匀,经静置、浇注、冷却后即得铸态的Zn-Li-Mg系锌合金(如图1所示)。Mixing, under the protection of CO 2 +SF 6 atmosphere, smelting at 600°C, stirring evenly, standing, pouring, and cooling to obtain cast Zn-Li-Mg zinc alloy (as shown in Figure 1).
实施例2、制备挤压态Zn-Li-Mg系锌合金Embodiment 2, preparation extruded state Zn-Li-Mg system zinc alloy
首先按照本发明实施例1中的步骤制备得到铸态的Zn-Li-Mg系锌合金锭,然后采用挤压的方式制备得到Zn-Li-Mg系锌合金棒材(如图2所示),采用径向挤压,铸锭保温2h,保温温度260℃或220℃,挤压温度为260℃或220℃,挤压比为36或16,挤压速度1mm/s制备出直径为10mm的Zn-Li-Mg系锌合金棒材,即挤压态Zn-Li-Mg系锌合金。First, the as-cast Zn-Li-Mg zinc alloy ingot is prepared according to the steps in Example 1 of the present invention, and then the Zn-Li-Mg zinc alloy rod is prepared by extrusion (as shown in Figure 2) , using radial extrusion, ingot insulation for 2 hours, insulation temperature 260 ℃ or 220 ℃, extrusion temperature 260 ℃ or 220 ℃, extrusion ratio 36 or 16, extrusion speed 1mm/s to prepare a diameter of 10mm Zn-Li-Mg series zinc alloy bar, that is, extruded Zn-Li-Mg series zinc alloy.
实施例3、制备轧制态Zn-Li-Mg系锌合金Embodiment 3, preparation rolling state Zn-Li-Mg system zinc alloy
首先按照本发明实施例1中的步骤制备得到铸态的Zn-Li-Mg系锌合金锭,然后采用轧制的方式制备Zn-Li-Mg系锌合金板材(如图3所示),采用单向轧制,依次进行热轧和精轧,轧制前在轧制温度270℃下保温15分钟,热轧在250℃下进行,精轧在200℃下进行,每道次轧下量2%,即得到1~3mm的轧制态Zn-Li-Mg系锌合金。Firstly, the as-cast Zn-Li-Mg system zinc alloy ingot is prepared according to the steps in Example 1 of the present invention, and then the Zn-Li-Mg system zinc alloy plate is prepared by rolling (as shown in Figure 3), using One-way rolling, hot rolling and finish rolling in sequence, before rolling, keep warm at the rolling temperature of 270°C for 15 minutes, hot rolling at 250°C, finish rolling at 200°C, and the amount of rolling in each pass is 2 %, that is, a rolled Zn-Li-Mg zinc alloy of 1 to 3 mm can be obtained.
实施例4、Zn-Li-Mg系锌合金力学性能测试Embodiment 4, Zn-Li-Mg system zinc alloy mechanical property test
将本发明中实施例1制备得到的Zn-Li-Mg系锌合金,分别按照ASTM-E8/E8M-09拉伸测试标准制备拉伸样品,车光。在丙酮、无水乙醇和去离子水中分别超声清洗15min后,采用万能材料力学试验机在室温下进行拉伸压缩试验,拉伸速度为0.05mm/mm·min。拉伸强度实验结果如表1所示。The Zn-Li-Mg series zinc alloy prepared in Example 1 of the present invention was used to prepare tensile samples according to the ASTM-E8/E8M-09 tensile test standard, respectively. After ultrasonic cleaning in acetone, absolute ethanol and deionized water for 15 min, the tensile and compressive tests were carried out at room temperature using a universal mechanical testing machine for materials with a tensile speed of 0.05 mm/mm min. The results of the tensile strength test are shown in Table 1.
表1 Zn-Li-Mg系锌合金力学性能Table 1 Mechanical properties of Zn-Li-Mg zinc alloys
由表1中结果可知,本发明Zn-Li-Mg系锌合金的屈服强度最高为470MPa,抗拉强度最高为681MPa,断后延伸率最高为8.92%。如表1中锌合金中添加0.1%或0.5%的Li的力学性能数据可知,通过微合金化加入Li元素能显著提高的材料的强度,通过进一步微合金化加入Mg元素可以进一步提高合金强度,Zn0.8Li0.1Mg的抗拉强度达到681MPa,其应力应变曲线如图4所示,本发明是目前有报道的可降解锌合金中强度最高的一种合金,其优异的力学性能能赋予材料更广的应用范围。It can be known from the results in Table 1 that the highest yield strength of the Zn-Li-Mg zinc alloy of the present invention is 470 MPa, the highest tensile strength is 681 MPa, and the highest elongation after fracture is 8.92%. As can be seen from the mechanical property data of zinc alloys with 0.1% or 0.5% Li added in Table 1, the strength of the material can be significantly improved by adding Li element through microalloying, and the alloy strength can be further improved by adding Mg element through further microalloying, The tensile strength of Zn0.8Li0.1Mg reaches 681MPa, and its stress-strain curve is as shown in Figure 4. The present invention is an alloy with the highest strength among the reported degradable zinc alloys, and its excellent mechanical properties can endow the material with more Wide range of applications.
实施例5、Zn-Li-Mg系锌合金腐蚀性能测试Embodiment 5, Zn-Li-Mg system zinc alloy corrosion performance test
将本发明实施例2中经挤压的Zn-Li-Mg系锌合金,通过线切割制备 Zn-Li-Mg系锌合金试样片,依次经400#、800#、1200#和2000#SiC砂纸系列打磨抛光。在丙酮、无水乙醇和去离子水中分别超声清洗15min后,25℃下干燥。之后进行电化学测试,电化学测试是将上述处理好的试样通过Autolab电化学工作站,在Hank’s模拟体液中进行电化学测试。(Hank’s模拟体液NaCl 8.0g,CaCl2 0.14g,KCl 0.4g,NaHCO3 0.35g,葡萄糖1.0g,MgCl2·6H2O 0.1g,Na2HPO4·2H2O 0.06g,KH2PO4 0.06g,MgSO4·7H2O 0.06g溶解于1L去离子水中)The extruded Zn-Li-Mg zinc alloy in Example 2 of the present invention was prepared by wire cutting The Zn-Li-Mg series zinc alloy specimens were ground and polished by 400#, 800#, 1200# and 2000# SiC sandpaper series in sequence. After ultrasonic cleaning in acetone, absolute ethanol and deionized water for 15 min, dry at 25 °C. Afterwards, the electrochemical test is carried out. The electrochemical test is to pass the above-mentioned treated sample through the Autolab electrochemical workstation, and perform the electrochemical test in Hank's simulated body fluid. (Hank's simulated body fluid NaCl 8.0g, CaCl 2 0.14g, KCl 0.4g, NaHCO 3 0.35g, glucose 1.0g, MgCl 2 6H 2 O 0.1g, Na 2 HPO 4 2H 2 O 0.06g, KH 2 PO 4 0.06g, MgSO 4 7H 2 O 0.06g dissolved in 1L deionized water)
图5是本发明Zn-Li-Mg系锌合金在Hank’s模拟体液中的阳极极化曲线,通过计算得出纯锌、本发明Zn-Li-Mg系锌合金的降解速度是1.74mm/year。Fig. 5 is the anodic polarization curve of the Zn-Li-Mg system zinc alloy of the present invention in Hank's simulated body fluid, and the degradation rate of pure zinc and the Zn-Li-Mg system zinc alloy of the present invention is 1.74mm/year through calculation.
实施例6、Zn-Li-Mg系锌合金的细胞相容性实验Example 6, Cytocompatibility experiment of Zn-Li-Mg zinc alloy
按本发明实施例2的方法制备得到的Zn-Li-Mg系锌合金,通过线切割制备试样片,经400#、800#、1200#和2000#SiC砂纸系列打磨抛光。在丙酮、无水乙醇和去离子水中分别超声清洗15min后,25℃下干燥。通过去离子水对试样进行接触角测试,试样经紫外线消毒灭菌,置于无菌孔板中,按试样表面积与含10%血清和1%双抗(青霉素加链霉素混合溶液)的DMEM细胞培养基按体积之比为1.25cm2/mL的比例加入DMEM细胞培养基,置于37℃、95%相对湿度、5%CO2培养箱中24h,得到Zn-Li-Mg合金100%浸提液原液,将浸提液密封,4℃冰箱保存备用。The Zn-Li-Mg series zinc alloy prepared by the method of Example 2 of the present invention is prepared by wire cutting The sample piece is ground and polished by 400#, 800#, 1200# and 2000# SiC sandpaper series. After ultrasonic cleaning in acetone, absolute ethanol and deionized water for 15 min, dry at 25 °C. Test the contact angle of the sample with deionized water. The sample is sterilized by ultraviolet rays, placed in a sterile orifice plate, and mixed with 10% serum and 1% double antibody (penicillin plus streptomycin mixed solution) according to the surface area of the sample. ) DMEM cell culture medium is added to the DMEM cell culture medium at a volume ratio of 1.25cm 2 /mL, and placed in a 37°C, 95% relative humidity, 5% CO 2 incubator for 24h to obtain a Zn-Li-Mg alloy 100% extraction solution stock solution, seal the extraction solution, and store it in a refrigerator at 4°C for later use.
稀释浸提液与细胞接种培养及结果观察:将HUVEC人脐静脉内皮细胞,VSMC平滑肌细胞和MC3T3-E1小鼠成骨细胞复苏、传代后,悬浮于DMEM细胞培养基中,接种于96孔培养板上,培养24小时后,阴性对照组加入DMEM细胞培养基,阳性对照组加入含10%DMSO的细胞培养基,实验组加入上述得到的Zn-Li-Mg合金稀释浸提液,使最终细胞浓度为2~5×104/mL。置于37℃、5%CO2培养箱中培养,1,2,4天后分别取出培养板,在倒置相差显微镜下观察活细胞的形态并通过CCK8试剂盒进行细胞存活率的测试。Dilution of extracts and cell inoculation culture and result observation: HUVEC human umbilical vein endothelial cells, VSMC smooth muscle cells and MC3T3-E1 mouse osteoblasts were recovered and passaged, suspended in DMEM cell culture medium, and inoculated in 96-well culture On the plate, after culturing for 24 hours, the negative control group was added with DMEM cell culture medium, the positive control group was added with 10% DMSO-containing cell culture medium, and the experimental group was added with the Zn-Li-Mg alloy dilution extract obtained above to make the final cell The concentration is 2~5×10 4 /mL. Place them in a 37°C, 5% CO 2 incubator for culture, take out the culture plates after 1, 2, and 4 days, observe the morphology of living cells under an inverted phase-contrast microscope, and test the cell viability with the CCK8 kit.
图6、图7和图8分别是VSMC细胞,HUVEC细胞和MC3T3-E1细胞在本发明100%Zn-Li-Mg系锌合金浸提液中的相对存活率,根据ISO-10993-5标准,从图中可以看出在培养时间内,本发明Zn-Li-Mg系锌合金浸提液的对三种细胞均无毒性,显示出良好的生物相容性。特别是对内皮细胞和成骨细胞还有明显的促进增殖的作用。符合作为可降解支架材料和骨科植入物的要求。Figure 6, Figure 7 and Figure 8 are VSMC cells, HUVEC cells and MC3T3-E1 cells in the 100% Zn-Li-Mg zinc alloy leaching solution of the present invention, the relative survival rate, according to the ISO-10993-5 standard, It can be seen from the figure that during the culture period, the Zn-Li-Mg system zinc alloy leaching solution of the present invention has no toxicity to the three kinds of cells, showing good biocompatibility. Especially for endothelial cells and osteoblasts, it also has a significant effect on promoting proliferation. Meets requirements as a biodegradable scaffold material and orthopedic implants.
实施例7、Zn-Li-Mg系锌合金血液相容性测试Embodiment 7, Zn-Li-Mg system zinc alloy blood compatibility test
将本发明实施例2经轧制的Zn-Li-Mg系锌合金,通过线切割制备 Zn-Li-Mg系锌合金试样片,经400#、800#、1200#和2000#SiC砂纸系列打磨抛光。在丙酮、无水乙醇和去离子水中分别超声清洗15min后,25℃下干燥。采集健康志愿者身上新鲜血液,置于内含3.8wt.%柠檬酸钠作为抗凝剂的抗凝管保存。用0.9%生理盐水按4:5的比例稀释制成稀释血液样本。将试样浸泡在10mL生理盐水,37±0.5℃保温30min,加入0.2mL稀释血液样本,37±0.5℃保温60min。采用10mL生理盐水作为阴性对照组,10mL去离子水作为阳性对照组。经3000rpm离心5分钟,取上清液用Unic-7200紫外可见分光光度计545nm测量吸光度OD值,设置三组平行样以进行统计学分析。The rolled Zn-Li-Mg zinc alloy of Example 2 of the present invention was prepared by wire cutting Zn-Li-Mg series zinc alloy specimens were ground and polished by 400#, 800#, 1200# and 2000# SiC sandpaper series. After ultrasonic cleaning in acetone, absolute ethanol and deionized water for 15 min, dry at 25 °C. Fresh blood was collected from healthy volunteers and stored in an anticoagulant tube containing 3.8wt.% sodium citrate as an anticoagulant. Dilute blood samples with 0.9% normal saline at a ratio of 4:5. Soak the sample in 10mL of normal saline, keep warm at 37±0.5°C for 30min, add 0.2mL diluted blood sample, and keep warm at 37±0.5°C for 60min. 10 mL of normal saline was used as a negative control group, and 10 mL of deionized water was used as a positive control group. After centrifugation at 3000rpm for 5 minutes, the supernatant was taken to measure the absorbance OD value with a Unic-7200 ultraviolet-visible spectrophotometer at 545nm, and three groups of parallel samples were set up for statistical analysis.
用以下公式计算溶血率:Calculate the hemolysis rate with the following formula:
溶血率=(实验组OD值-阴性组OD值)/(阳性组OD值-阴性组OD值)×100%。Hemolysis rate=(OD value of experimental group-OD value of negative group)/(OD value of positive group-OD value of negative group)×100%.
由实验结果显示,本发明Zn-Li-Mg系锌合金的溶血率为1%左右,远远小于临床使用要求的安全阈值5%,表现出良好血液相容性。血小板粘附实验显示(如图9所示),粘附在本发明Zn-Li-Mn系锌合金表面的血小板形态正常,仅有轻微激活。Experimental results show that the hemolysis rate of the Zn-Li-Mg zinc alloy of the present invention is about 1%, far below the safety threshold of 5% required for clinical use, and shows good blood compatibility. Platelet adhesion experiments showed (as shown in FIG. 9 ) that the platelets adhered to the surface of the Zn-Li-Mn zinc alloy of the present invention had normal morphology and were only slightly activated.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810244009.5A CN108277386A (en) | 2018-03-23 | 2018-03-23 | A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810244009.5A CN108277386A (en) | 2018-03-23 | 2018-03-23 | A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108277386A true CN108277386A (en) | 2018-07-13 |
Family
ID=62810318
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810244009.5A Pending CN108277386A (en) | 2018-03-23 | 2018-03-23 | A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108277386A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109797315A (en) * | 2019-03-01 | 2019-05-24 | 湖南华耀百奥医疗科技有限公司 | A kind of medical degradable Zinc-base compounded material and the preparation method and application thereof |
CN109908408A (en) * | 2019-03-18 | 2019-06-21 | 何煜冰 | A kind of preparation method and application of the pure Zinc material of human body degradable biological |
CN111187943A (en) * | 2020-01-21 | 2020-05-22 | 西安爱德万思医疗科技有限公司 | Biomedical Zn-Cu-Mg alloy and preparation method thereof |
CN111778429A (en) * | 2020-07-31 | 2020-10-16 | 湖南华耀百奥医疗科技有限公司 | Degradable intravascular stent made of zinc-based alloy material and preparation method thereof |
CN112891640A (en) * | 2021-01-20 | 2021-06-04 | 湖南华锐科技集团股份有限公司 | Zn-Mg series zinc alloy intravascular stent and preparation method thereof |
CN112899527A (en) * | 2021-01-20 | 2021-06-04 | 湖南华锐科技集团股份有限公司 | Degradable zinc alloy bar and preparation method thereof |
CN113018515A (en) * | 2021-03-04 | 2021-06-25 | 湖南华锐科技集团股份有限公司 | Degradable zinc-based alloy bone fixation system material and preparation method thereof |
CN113427019A (en) * | 2021-06-22 | 2021-09-24 | 清华大学 | Method for manufacturing composite material and metal bone implant with structural function |
CN113528870A (en) * | 2021-07-15 | 2021-10-22 | 东南大学 | A kind of degradable Zn-Li-X alloy wire and preparation method thereof |
US11351290B1 (en) * | 2020-04-08 | 2022-06-07 | Admtech, Llc | Absorbable high-strength zinc alloy for medical implants |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005018356A1 (en) * | 2005-04-20 | 2006-10-26 | Orlowski, Michael, Dr. | Resorbable implant consisting mainly of zinc or zinc alloy, particularly useful as stent in blood vessels, urinary tract, respiratory tract, biliary tract or digestive tract, provides support until adequate tissue regeneration has occurred |
CN104212998A (en) * | 2014-08-21 | 2014-12-17 | 北京大学 | Zn-Mg zinc alloy and preparation method and application thereof |
CN106319287A (en) * | 2016-08-25 | 2017-01-11 | 上海交通大学 | Biodegradable medical Zn-Li-X series alloy material and preparation method and application |
CN107460371A (en) * | 2016-06-02 | 2017-12-12 | 北京大学 | A kind of Zn-Li systems kirsite and preparation method and application |
-
2018
- 2018-03-23 CN CN201810244009.5A patent/CN108277386A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005018356A1 (en) * | 2005-04-20 | 2006-10-26 | Orlowski, Michael, Dr. | Resorbable implant consisting mainly of zinc or zinc alloy, particularly useful as stent in blood vessels, urinary tract, respiratory tract, biliary tract or digestive tract, provides support until adequate tissue regeneration has occurred |
CN104212998A (en) * | 2014-08-21 | 2014-12-17 | 北京大学 | Zn-Mg zinc alloy and preparation method and application thereof |
CN107460371A (en) * | 2016-06-02 | 2017-12-12 | 北京大学 | A kind of Zn-Li systems kirsite and preparation method and application |
CN106319287A (en) * | 2016-08-25 | 2017-01-11 | 上海交通大学 | Biodegradable medical Zn-Li-X series alloy material and preparation method and application |
Non-Patent Citations (4)
Title |
---|
HAIBO GONG ET AL.: "In vitro biodegradation behavior, mechanical properties, and cytotoxicity of biodegradable Zn–Mg alloy", 《JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART B》 * |
SHANZHAO ET AL.: "Zn-Li alloy after extrusion and drawing: Structural, mechanical characterization, and biodegradation in abdominal aorta of rat", 《MATERIALS SCIENCE AND ENGINEERING: C》 * |
XIWEILIU ET AL.: "Micro-alloying with Mn in Zn–Mg alloy for future biodegradable Materials & Design", 《METALS APPLICATION》 * |
郑玉峰等: "生物可降解镁合金的发展现状与展望", 《中国材料进展》 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109797315A (en) * | 2019-03-01 | 2019-05-24 | 湖南华耀百奥医疗科技有限公司 | A kind of medical degradable Zinc-base compounded material and the preparation method and application thereof |
CN109908408A (en) * | 2019-03-18 | 2019-06-21 | 何煜冰 | A kind of preparation method and application of the pure Zinc material of human body degradable biological |
CN111187943A (en) * | 2020-01-21 | 2020-05-22 | 西安爱德万思医疗科技有限公司 | Biomedical Zn-Cu-Mg alloy and preparation method thereof |
US11351290B1 (en) * | 2020-04-08 | 2022-06-07 | Admtech, Llc | Absorbable high-strength zinc alloy for medical implants |
CN111778429A (en) * | 2020-07-31 | 2020-10-16 | 湖南华耀百奥医疗科技有限公司 | Degradable intravascular stent made of zinc-based alloy material and preparation method thereof |
CN112899527B (en) * | 2021-01-20 | 2022-04-08 | 湖南华锐科技集团股份有限公司 | Degradable zinc alloy bar and preparation method thereof |
CN112899527A (en) * | 2021-01-20 | 2021-06-04 | 湖南华锐科技集团股份有限公司 | Degradable zinc alloy bar and preparation method thereof |
CN112891640A (en) * | 2021-01-20 | 2021-06-04 | 湖南华锐科技集团股份有限公司 | Zn-Mg series zinc alloy intravascular stent and preparation method thereof |
CN112891640B (en) * | 2021-01-20 | 2022-06-28 | 湖南华锐科技集团股份有限公司 | Zn-Mg series zinc alloy intravascular stent and preparation method thereof |
CN113018515A (en) * | 2021-03-04 | 2021-06-25 | 湖南华锐科技集团股份有限公司 | Degradable zinc-based alloy bone fixation system material and preparation method thereof |
CN113018515B (en) * | 2021-03-04 | 2022-09-13 | 湖南华锐科技集团股份有限公司 | Degradable zinc-based alloy bone fixation system material and preparation method thereof |
CN113427019A (en) * | 2021-06-22 | 2021-09-24 | 清华大学 | Method for manufacturing composite material and metal bone implant with structural function |
CN113427019B (en) * | 2021-06-22 | 2023-03-10 | 清华大学 | Method for manufacturing composite material and metal bone implant with structural function |
CN113528870A (en) * | 2021-07-15 | 2021-10-22 | 东南大学 | A kind of degradable Zn-Li-X alloy wire and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108277386A (en) | A kind of Zn-Li-Mg systems kirsite and the preparation method and application thereof | |
CN108315583B (en) | Zn-Li-Mn zinc alloy and preparation method and application thereof | |
CN104212998B (en) | Zn-Mg zinc alloy and preparation method and application thereof | |
Wang et al. | Research progress of biodegradable magnesium-based biomedical materials: A review | |
CN104195368B (en) | A kind of Zn-Sr system kirsite and preparation method and application | |
CN109680195B (en) | A kind of Mg-RE series magnesium alloy and its preparation method and application | |
CN104195369B (en) | A kind of Zn-Ca system kirsite and preparation method and application | |
CN106467942B (en) | Biodegradable medical pltine and its preparation method and application | |
CN107460371B (en) | A kind of Zn-Li series zinc alloy and its preparation method and application | |
CN104911427B (en) | A kind of Mg Ca Sr Zn systems magnesium alloy and preparation method and application | |
CN101837145B (en) | High-toughness corrosion-resistant magnesium alloy implanted material capable of being degraded in organism | |
WO2017084363A1 (en) | Medical degradable zn-cu-x alloy material and preparation method thereof | |
CN101899600B (en) | Orthopedic magnesium alloy implant material and preparation method thereof | |
CN108754232B (en) | A high-strength and high-plastic biodegradable Zn-Mn-Li series zinc alloy and use thereof | |
WO2018000219A1 (en) | Degradable corrosion-resistant high strength and ductility magnesium alloy for biomedical use and preparation method therefor | |
JP2014534338A (en) | Biodegradable metal alloy | |
CN102978493B (en) | Mg-Li magnesium alloy and preparation method thereof | |
CN107456601A (en) | A kind of Zn-Cu systems kirsite and preparation method and application | |
CN107190191B (en) | A kind of biological medical magnesium alloy and preparation method thereof | |
CN107460372A (en) | A kind of Zn Mn systems kirsite and preparation method and application | |
CN106606806B (en) | A kind of Zn-Mg1Ca system kirsite and the preparation method and application thereof | |
CN111676390B (en) | A kind of Zn-Ga series alloy and its preparation method and application | |
CN108165782B (en) | A kind of medical zinc-based alloy strip and preparation method thereof | |
CN107198796B (en) | A kind of biomedical Zn-Mn-Cu series zinc alloy and preparation method thereof | |
CN106606801A (en) | Zn-ZnO zinc alloy and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180713 |
|
RJ01 | Rejection of invention patent application after publication |